{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of confidence interval not estimable due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"3.25","upperLimit":"NA","value":"8.8"},{"groupId":"OG001","lowerLimit":"7.66","upperLimit":"26.22","value":"13.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"44"}],"units":"Participants"}],"description":"OS defined as the time from first study drug administration to the date of death due to any reason for cohorts 1 and 2.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed or refractory (R/R) extranodal natural killer-/T-cell lymphoma (ENKTL; nasal or non-nasal type) were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)","id":"OG000","title":"Cohort 1: ENKTL"},{"description":"Participants with other R/R mature T-cell neoplasms \\[limited to peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL)\\] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)","id":"OG001","title":"Cohort 2: PTCL-NOS, AITL, and ALCL"}],"paramType":"MEDIAN","populationDescription":"Safety analysis set includes all participants who received at least one dose of study drug","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years and 1 week","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}